Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. / Kolberg, Janice A; Jørgensen, Torben; Gerwien, Robert W; Hamren, Sarah; McKenna, Michael P; Moler, Edward; Rowe, Michael W; Urdea, Mickey S; Xu, Xiaomei M; Hansen, Torben; Pedersen, Oluf; Borch-Johnsen, Knut.

In: Diabetes Care, Vol. 32, No. 7, 2009, p. 1207-12.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Kolberg, JA, Jørgensen, T, Gerwien, RW, Hamren, S, McKenna, MP, Moler, E, Rowe, MW, Urdea, MS, Xu, XM, Hansen, T, Pedersen, O & Borch-Johnsen, K 2009, 'Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort', Diabetes Care, vol. 32, no. 7, pp. 1207-12. https://doi.org/10.2337/dc08-1935

APA

Kolberg, J. A., Jørgensen, T., Gerwien, R. W., Hamren, S., McKenna, M. P., Moler, E., Rowe, M. W., Urdea, M. S., Xu, X. M., Hansen, T., Pedersen, O., & Borch-Johnsen, K. (2009). Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes Care, 32(7), 1207-12. https://doi.org/10.2337/dc08-1935

Vancouver

Kolberg JA, Jørgensen T, Gerwien RW, Hamren S, McKenna MP, Moler E et al. Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes Care. 2009;32(7):1207-12. https://doi.org/10.2337/dc08-1935

Author

Kolberg, Janice A ; Jørgensen, Torben ; Gerwien, Robert W ; Hamren, Sarah ; McKenna, Michael P ; Moler, Edward ; Rowe, Michael W ; Urdea, Mickey S ; Xu, Xiaomei M ; Hansen, Torben ; Pedersen, Oluf ; Borch-Johnsen, Knut. / Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. In: Diabetes Care. 2009 ; Vol. 32, No. 7. pp. 1207-12.

Bibtex

@article{41a5217071f911de8bc9000ea68e967b,
title = "Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort",
abstract = "OBJECTIVE: The purpose of this study was to develop a model for assessing the 5-year risk of developing type 2 diabetes from a panel of 64 circulating candidate biomarkers. RESEARCH DESIGN AND METHODS: Subjects were selected from the Inter99 cohort, a longitudinal population-based study of approximately 6,600 Danes in a nested case-control design with the primary outcome of 5-year conversion to type 2 diabetes. Nondiabetic subjects, aged >or=39 years, with BMI >or=25 kg/m(2) at baseline were selected. Baseline fasting serum samples from 160 individuals who developed type 2 diabetes and from 472 who did not were tested. An ultrasensitive immunoassay was used to measure of 58 candidate biomarkers in multiple diabetes-associated pathways, along with six routine clinical variables. Statistical learning methods and permutation testing were used to select the most informative biomarkers. Risk model performance was estimated using a validated bootstrap bias-correction procedure. RESULTS: A model using six biomarkers (adiponectin, C-reactive protein, ferritin, interleukin-2 receptor A, glucose, and insulin) was developed for assessing an individual's 5-year risk of developing type 2 diabetes. This model has a bootstrap-estimated area under the curve of 0.76, which is greater than that for A1C, fasting plasma glucose, fasting serum insulin, BMI, sex-adjusted waist circumference, a model using fasting glucose and insulin, and a noninvasive clinical model. CONCLUSIONS: A model incorporating six circulating biomarkers provides an objective and quantitative estimate of the 5-year risk of developing type 2 diabetes, performs better than single risk indicators and a noninvasive clinical model, and provides better stratification than fasting plasma glucose alone.",
author = "Kolberg, {Janice A} and Torben J{\o}rgensen and Gerwien, {Robert W} and Sarah Hamren and McKenna, {Michael P} and Edward Moler and Rowe, {Michael W} and Urdea, {Mickey S} and Xu, {Xiaomei M} and Torben Hansen and Oluf Pedersen and Knut Borch-Johnsen",
year = "2009",
doi = "10.2337/dc08-1935",
language = "English",
volume = "32",
pages = "1207--12",
journal = "Diabetes Care",
issn = "0149-5992",
publisher = "American Diabetes Association",
number = "7",

}

RIS

TY - JOUR

T1 - Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort

AU - Kolberg, Janice A

AU - Jørgensen, Torben

AU - Gerwien, Robert W

AU - Hamren, Sarah

AU - McKenna, Michael P

AU - Moler, Edward

AU - Rowe, Michael W

AU - Urdea, Mickey S

AU - Xu, Xiaomei M

AU - Hansen, Torben

AU - Pedersen, Oluf

AU - Borch-Johnsen, Knut

PY - 2009

Y1 - 2009

N2 - OBJECTIVE: The purpose of this study was to develop a model for assessing the 5-year risk of developing type 2 diabetes from a panel of 64 circulating candidate biomarkers. RESEARCH DESIGN AND METHODS: Subjects were selected from the Inter99 cohort, a longitudinal population-based study of approximately 6,600 Danes in a nested case-control design with the primary outcome of 5-year conversion to type 2 diabetes. Nondiabetic subjects, aged >or=39 years, with BMI >or=25 kg/m(2) at baseline were selected. Baseline fasting serum samples from 160 individuals who developed type 2 diabetes and from 472 who did not were tested. An ultrasensitive immunoassay was used to measure of 58 candidate biomarkers in multiple diabetes-associated pathways, along with six routine clinical variables. Statistical learning methods and permutation testing were used to select the most informative biomarkers. Risk model performance was estimated using a validated bootstrap bias-correction procedure. RESULTS: A model using six biomarkers (adiponectin, C-reactive protein, ferritin, interleukin-2 receptor A, glucose, and insulin) was developed for assessing an individual's 5-year risk of developing type 2 diabetes. This model has a bootstrap-estimated area under the curve of 0.76, which is greater than that for A1C, fasting plasma glucose, fasting serum insulin, BMI, sex-adjusted waist circumference, a model using fasting glucose and insulin, and a noninvasive clinical model. CONCLUSIONS: A model incorporating six circulating biomarkers provides an objective and quantitative estimate of the 5-year risk of developing type 2 diabetes, performs better than single risk indicators and a noninvasive clinical model, and provides better stratification than fasting plasma glucose alone.

AB - OBJECTIVE: The purpose of this study was to develop a model for assessing the 5-year risk of developing type 2 diabetes from a panel of 64 circulating candidate biomarkers. RESEARCH DESIGN AND METHODS: Subjects were selected from the Inter99 cohort, a longitudinal population-based study of approximately 6,600 Danes in a nested case-control design with the primary outcome of 5-year conversion to type 2 diabetes. Nondiabetic subjects, aged >or=39 years, with BMI >or=25 kg/m(2) at baseline were selected. Baseline fasting serum samples from 160 individuals who developed type 2 diabetes and from 472 who did not were tested. An ultrasensitive immunoassay was used to measure of 58 candidate biomarkers in multiple diabetes-associated pathways, along with six routine clinical variables. Statistical learning methods and permutation testing were used to select the most informative biomarkers. Risk model performance was estimated using a validated bootstrap bias-correction procedure. RESULTS: A model using six biomarkers (adiponectin, C-reactive protein, ferritin, interleukin-2 receptor A, glucose, and insulin) was developed for assessing an individual's 5-year risk of developing type 2 diabetes. This model has a bootstrap-estimated area under the curve of 0.76, which is greater than that for A1C, fasting plasma glucose, fasting serum insulin, BMI, sex-adjusted waist circumference, a model using fasting glucose and insulin, and a noninvasive clinical model. CONCLUSIONS: A model incorporating six circulating biomarkers provides an objective and quantitative estimate of the 5-year risk of developing type 2 diabetes, performs better than single risk indicators and a noninvasive clinical model, and provides better stratification than fasting plasma glucose alone.

U2 - 10.2337/dc08-1935

DO - 10.2337/dc08-1935

M3 - Journal article

C2 - 19564473

VL - 32

SP - 1207

EP - 1212

JO - Diabetes Care

JF - Diabetes Care

SN - 0149-5992

IS - 7

ER -

ID: 13206303